

wise applicable statute of limitations, may implead a biomaterials supplier who has been dismissed from the action pursuant to this chapter if—

(1) the manufacturer has made an assertion, either in a motion or other pleading filed with the court or in an opening or closing statement at trial, or as part of a claim for contribution or indemnification, and the court finds based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the manufacturer's liability for damages should be reduced in whole or in part because of such negligence or intentionally tortious conduct; or

(2) the claimant has moved to implead the supplier and the court finds, based on the court's independent review of the evidence contained in the record of the action, that under applicable law—

(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and

(B) the claimant is unlikely to be able to recover the full amount of its damages from the remaining defendants.

(b) Standard of liability

Notwithstanding any preliminary finding under subsection (a) of this section, a biomaterials supplier who has been impleaded into an action covered by this chapter, as provided for in this section—

(1) may, prior to entry of judgment on the claim against it, supplement the record of the proceeding that was developed prior to the grant of the motion for impleader under subsection (a) of this section; and

(2) may be found liable to a manufacturer or a claimant only to the extent required and permitted by any applicable State or Federal law other than this chapter.

(c) Discovery

Nothing in this section shall give a claimant or any other party the right to obtain discovery from a biomaterials supplier at any time prior to grant of a motion for impleader beyond that allowed under section 1605 of this title.

(Pub. L. 105-230, §7, Aug. 13, 1998, 112 Stat. 1528.)

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in sections 1603, 1604, 1605 of this title.

CHAPTER 22—NATIONAL DRUG CONTROL POLICY

- Sec. 1701. Definitions.
- 1702. Office of National Drug Control Policy.
 - (a) Establishment of Office.
 - (b) Director and Deputy Directors.
 - (c) Access by Congress.
 - (d) Office of National Drug Control Policy Gift Fund.

- Sec. 1703. Appointment and duties of Director and Deputy Directors.
 - (a) Appointment.
 - (b) Responsibilities.
 - (c) National Drug Control Program budget.
 - (d) Powers of the Director.
 - (e) Personnel detailed to Office.
 - (f) Fund control notices.
 - (g) Inapplicability to certain programs.
 - (h) Construction.
- 1704. Coordination with National Drug Control Program agencies in demand reduction, supply reduction, and State and local affairs.
 - (a) Access to information.
 - (b) Certification of policy changes to Director.
 - (c) General Services Administration.
 - (d) Accounting of funds expended.
- 1705. Development, submission, implementation, and assessment of National Drug Control Strategy.
 - (a) Timing, contents, and process for development and submission of National Drug Control Strategy.
 - (b) Annual strategy report.
 - (c) Performance measurement system.
- 1706. High Intensity Drug Trafficking Areas Program.
 - (a) Establishment.
 - (b) Designation.
 - (c) Factors for consideration.
 - (d) Use of funds.
- 1707. Counter-Drug Technology Assessment Center.
 - (a) Establishment.
 - (b) Director of Technology.
 - (c) Additional responsibilities of the Director of National Drug Control Policy.
 - (d) Assistance and support to Office of National Drug control Policy.
- 1708. President's Council on Counter-Narcotics.
 - (a) Establishment.
 - (b) Membership.
 - (c) Functions.
 - (d) Administration.
- 1709. Parents Advisory Council on Youth Drug Abuse.
 - (a) In general.
 - (b) Duties of Council.
 - (c) Expenses.
 - (d) Authorization of appropriations.
- 1710. Drug interdiction.
 - (a) Definition.
 - (b) Report.
 - (c) Budget process.
- 1711. Authorization of appropriations.
- 1712. Termination of Office of National Drug Control Policy.
 - (a) In general.
 - (b) Exception.
- 1713. Authorization of use of environmentally-approved herbicides to eliminate illicit narcotics crops.

§ 1701. Definitions

In this chapter:

(1) Demand reduction

The term "demand reduction" means any activity conducted by a National Drug Control Program agency, other than an enforcement activity, that is intended to reduce the use of drugs, including—

- (A) drug abuse education;
- (B) drug abuse prevention;

- (C) drug abuse treatment;
- (D) drug abuse research;
- (E) drug abuse rehabilitation;
- (F) drug-free workplace programs; and
- (G) drug testing.

(2) Director

The term “Director” means the Director of National Drug Control Policy.

(3) Drug

The term “drug” has the meaning given the term “controlled substance” in section 802(6) of this title.

(4) Drug control

The term “drug control” means any activity conducted by a National Drug Control Program agency involving supply reduction or demand reduction.

(5) Fund

The term “Fund” means the fund established under section 1702(d) of this title.

(6) National Drug Control Program

The term “National Drug Control Program” means programs, policies, and activities undertaken by National Drug Control Program agencies pursuant to the responsibilities of such agencies under the National Drug Control Strategy.

(7) National Drug Control Program agency

The term “National Drug Control Program agency” means any agency that is responsible for implementing any aspect of the National Drug Control Strategy, including any agency that receives Federal funds to implement any aspect of the National Drug Control Strategy, but does not include any agency that receives funds for drug control activity solely under the National Foreign Intelligence Program, the Joint Military Intelligence Program or Tactical Intelligence and Related Activities, unless such agency has been designated—

- (A) by the President; or
- (B) jointly by the Director and the head of the agency.

(8) National Drug Control Strategy

The term “National Drug Control Strategy” means the strategy developed and submitted to Congress under section 1705 of this title.

(9) Office

Unless the context clearly implicates otherwise, the term “Office” means the Office of National Drug Control Policy established under section 1702(a) of this title.

(10) State and local affairs

The term “State and local affairs” means domestic activities conducted by a National Drug Control Program agency that are intended to reduce the availability and use of drugs, including—

- (A) coordination and facilitation of Federal, State, and local law enforcement drug control efforts;
- (B) promotion of coordination and cooperation among the drug supply reduction and demand reduction agencies of the various States, territories, and units of local government; and

- (C) such other cooperative governmental activities which promote a comprehensive approach to drug control at the national, State, territory, and local levels.

(11) Supply reduction

The term “supply reduction” means any activity of a program conducted by a National Drug Control Program agency that is intended to reduce the availability or use of drugs in the United States and abroad, including—

- (A) international drug control;
- (B) foreign and domestic drug intelligence;
- (C) interdiction; and
- (D) domestic drug law enforcement, including law enforcement directed at drug users.

(Pub. L. 105-277, div. C, title VII, §702, Oct. 21, 1998, 112 Stat. 2681-670.)

REPEAL OF SECTION

For repeal of section on Sept. 30, 2003, see section 1712 of this title.

REFERENCES IN TEXT

This chapter, referred to in text, was in the original “this title”, meaning title VII of div. C of Pub. L. 105-277, Oct. 21, 1998, 112 Stat. 2681-670, known as Office of National Drug Control Policy Reauthorization Act of 1998, which is classified principally to this chapter. For complete classification of title VII to the Code, see Short Title note set out below and Tables.

SHORT TITLE

Pub. L. 105-277, div. C, title VII, §701, Oct. 21, 1998, 112 Stat. 2681-670, provided that: “This title [enacting this chapter, amending section 1509 of this title, sections 5312 to 5314 of Title 5, Government Organization and Employees, section 1105 of Title 31, Money and Finance, and section 402 of Title 50, War and National Defense] may be cited as the ‘Office of National Drug Control Policy Reauthorization Act of 1998’.”

EX. ORD. No. 13165. WHITE HOUSE TASK FORCE ON DRUG USE IN SPORTS AND UNITED STATES REPRESENTATIVE ON THE BOARD OF THE WORLD ANTI-DOPING AGENCY

Ex. Ord. No. 13165, Aug. 9, 2000, 65 F.R. 49469, as amended by Ex. Ord. No. 13286, §11, Feb. 28, 2003, 68 F.R. 10622, provided:

By the authority vested in me as President by the Constitution and the laws of the United States of America, including the Office of National Drug Control [Policy] Reauthorization Act of 1998, (21 U.S.C. 1701 *et seq.*), and in order to develop recommendations for Federal agency actions to address the use of drugs in sports, in particular among young people, it is hereby ordered as follows:

SECTION 1. *Policy.* The use of drugs in sports has reached a level that endangers not just the legitimacy of athletic competition but also the lives and health of athletes—from the elite ranks to youth leagues. The National Household Survey on Drug Abuse issued in 1999 found that in just 1 year’s time the rate of steroid use among young people rose roughly 50 percent among both sexes and across all age groups. It is the policy of my Administration to take the steps needed to help eliminate illicit or otherwise banned drug use and doping in sports at the State, national, and international level.

SEC. 2. *Establishment of a White House Task Force on Drug Use in Sports.* (a) There is established a White House Task Force on Drug Use in Sports (Task Force). The Task Force shall comprise the co-vice chairs of the White House Olympic Task Force (the “Olympic Task Force Vice Chairs”), and representatives designated by the Office of National Drug Control Policy, the Depart-

ment of Health and Human Services, the Department of Labor, the President's Council on Physical Fitness and Sports, the Office of Management and Budget, the National Security Council, the Department of State, the Department of the Treasury, the Department of Education, the Department of Justice, the Department of Transportation, the Department of Homeland Security, the National Institute on Drug Abuse, and the Substance Abuse and Mental Health Services Administration.

(b) The Task Force shall develop recommendations for the President on further executive and legislative actions that can be undertaken to address the problem of doping and drug use in sports. In developing the recommendations, the Task Force shall consider, among other things: (i) the health and safety of America's athletes, in particular our Nation's young people; (ii) the integrity of honest athletic competition; and (iii) the views and recommendations of State and local governments, the private sector, citizens, community groups, and nonprofit organizations, on actions to address this threat. The Task Force, through its Chairs, shall submit its recommendations to the President.

(c) The Director of the Office of National Drug Control Policy (the Director), the Secretary of the Department of Health and Human Services, and the Olympic Task Force Vice Chairs or their designees shall serve as the Task Force Chairs.

(d) To the extent permitted by law and at the request of the Chairs, agencies shall cooperate with and provide information to the Task Force.

SEC. 3. *Participation in the World Anti-Doping Agency.*
(a) As part of my Administration's efforts to address the problem of drug use in sports, the United States has played a leading role in the formation of a World Anti-Doping Agency (WADA) by the Olympic and sports community and the nations of the world. Through these efforts, the United States has been selected to serve as a governmental representative on the board of the WADA. This order will authorize the Director to serve as the United States Government's representative on the WADA board.

(b) Pursuant to 21 U.S.C. 1701 *et seq.*, the Director, or in his absence his designee, is hereby authorized to take all necessary and proper actions to execute his responsibilities as United States representative to the WADA.

(c) To assist the Director in carrying out these responsibilities as the United States Government representative to the WADA and to the extent permitted by law, Federal employees may serve in their official capacity, *inter alia*, on WADA Committees or WADA advisory committees, serving as experts to the WADA.

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in section 1702 of this title.

§ 1702. Office of National Drug Control Policy

(a) Establishment of Office

There is established in the Executive Office of the President an Office of National Drug Control Policy, which shall—

- (1) develop national drug control policy;
- (2) coordinate and oversee the implementation of that national drug control policy;
- (3) assess and certify the adequacy of national drug control programs and the budget for those programs; and
- (4) evaluate the effectiveness of the national drug control programs.

(b) Director and Deputy Directors

(1) Director

There shall be at the head of the Office a Director of National Drug Control Policy.

(2) Deputy Director of National Drug Control Policy

There shall be in the Office a Deputy Director of National Drug Control Policy, who shall assist the Director in carrying out the responsibilities of the Director under this chapter.

(3) Other Deputy Directors

There shall be in the Office—

(A) a Deputy Director for Demand Reduction, who shall be responsible for the activities described in subparagraphs (A) through (G) of section 1701(1) of this title;

(B) a Deputy Director for Supply Reduction, who shall be responsible for the activities described in subparagraphs (A) through (C) of section 1701(11) of this title; and

(C) a Deputy Director for State and Local Affairs, who shall be responsible for the activities described in subparagraphs (A) through (C) of section 1701(10) of this title and subparagraph (D) of section 1701(11) of this title.

(c) Access by Congress

The location of the Office in the Executive Office of the President shall not be construed as affecting access by Congress, or any committee of the House of Representatives or the Senate, to any—

(1) information, document, or study in the possession of, or conducted by or at the direction of the Director; or

(2) personnel of the Office.

(d) Office of National Drug Control Policy Gift Fund

(1) Establishment

There is established in the Treasury of the United States a fund for the receipt of gifts, both real and personal, for the purpose of aiding or facilitating the work of the Office under section 1703(c) of this title.

(2) Contributions

The Office may accept, hold, and administer contributions to the Fund.

(3) Use of amounts deposited

Amounts deposited in the Fund are authorized to be appropriated, to remain available until expended for authorized purposes at the discretion of the Director.

(Pub. L. 105-277, div. C, title VII, §703, Oct. 21, 1998, 112 Stat. 2681-672.)

REPEAL OF SECTION

For repeal of section on Sept. 30, 2003, see section 1712 of this title.

GIFTS TO OFFICE OF NATIONAL DRUG CONTROL POLICY

Pub. L. 107-67, title III, Nov. 12, 2001, 115 Stat. 530, provided in part: "That the Office [of National Drug Control Policy] is authorized to accept, hold, administer, and utilize gifts, both real and personal, public and private, without fiscal year limitation, for the purpose of aiding or facilitating the work of the Office."

Similar provisions were contained in the following prior appropriation acts:

Pub. L. 106-554, §1(a)(3) [title III], Dec. 21, 2000, 114 Stat. 2763, 2763A-139.

Pub. L. 106-58, title III, Sept. 29, 1999, 113 Stat. 447.

Pub. L. 105-277, div. A, §101(h) [title III], Oct. 21, 1998, 112 Stat. 2681-480, 2681-496.